Many smokers believe that electronic nicotine delivery systems (ENDS) and pharmaceutical cessation aids can help them quit smoking or reduce cigarette consumption, but the evidence for e-cigarettes to aid quitting is limited. Examining 3,093 quit attempters in the nationally representative US Population Assessment of Tobacco and Health (PATH) Study, using data from 2013-2015, we evaluated the influence of ENDS and pharmaceutical cessation aids on persistent abstinence (≥30 days) from cigarettes and reduced cigarette consumption, using propensity score matching to balance comparison groups on potential confounders and multiple imputation to handle missing data. At PATH Wave 2, 25.2% of quit attempters reported using ENDS to quit during the previous year, making it the most popular cessation aid in 2014-2015. More quit attempters were persistently cigarette abstinent than were persistently tobacco abstinent (15.5% (standard error, 0.8) vs. 9.6% (standard error, 0.6)). Using ENDS to quit cigarettes increased the probability of persistent cigarette abstinence at Wave 2 (risk difference (RD) = 6%, 95% confidence interval (CI): 2, 10), but using approved pharmaceutical aids did not (for varenicline, RD = 2%, 95% CI: −6, 13; for bupropion, RD = 4%, 95% CI: −6, 17; for nicotine replacement therapy, RD = −3%, 95% CI: −8, 2). Among quit attempters who relapsed, ENDS did not reduce the average daily cigarette consumption (cigarettes per day, −0.18, 95% CI: −1.87, 1.51).
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Electronic nicotine delivery systems (ENDS) became commercially available in the United States in 2007, when the rates of smoking cessation had stalled (1) . A recent comprehensive National Academies of Sciences, Engineering, and Medicine report (2) concluded that e-cigarettes have lower levels of toxicants than is found in smoke from combusted tobacco cigarettes, and experienced adult users of third-generation e-cigarettes (e.g., advanced personal vaporizers) are able to extract similar levels of nicotine to the those amounts obtained from cigarette smoking (3) . The National Academies of Sciences, Engineering, and Medicine report also noted: "For both individuals and for public health, the central potential benefit of e-cigarettes is to promote smoking cessation among established cigarette smokers or at least to reduce a smoker's exposure to combustible tobacco products" (2, p. 423). At the same time, there is substantial evidence that e-cigarette use in young people increases the risk of future cigarette smoking (4) .
Current prevalence estimates for ENDS use in the United States vary with surveys, with Wave 1 of the US Population Assessment of Tobacco and Health (PATH) Study (2013-2014) indicating that 5.5% of the population were current users (5) and the 2014-15 Tobacco Use Supplement of the Current Population Survey indicating a lower 2.4% (1) . In this latter survey, current ENDS use rates were 19.0% for recent quitters and 11.5% for current smokers, with the majority being nondaily users. In the PATH Study, 83.5% of current and 76% of former cigarettes smokers (5) agreed that e-cigarettes could substitute in places where cigarettes were proscribed. Similarly, approximately 75% agreed that e-cigarettes can help people quit smoking cigarettes.
There is a substantial literature of randomized controlled trials showing the efficacy of nicotine replacement, varenicline, and bupropion as smoking cessation aids (6) but few trials of e-cigarettes. For e-cigarettes, meta-analyses (2) consistently identify only 2 international trials that appropriately address the role of e-cigarettes in cessation. Bullen et al. (7) randomized smokers who wanted to quit to either e-cigarettes, nicotine patches, or placebo e-cigarette. Biochemically verified 6-months continuous abstinence was not significantly higher in the e-cigarette group than in the nicotine patch group or the placebo control (7.3% vs. 5.8% vs. 4.1%). Caponnetto et al. (8) compared e-cigarettes with a placebo e-cigarette, and verified 6-months continuous abstinence was 11% vs. 4%, which reached borderline significance.
In contrast to randomized trials, population-based longitudinal studies reflect how e-cigarettes are actually being used in the target population. Six longitudinal studies of e-cigarettes in cessation (9) (10) (11) (12) (13) (14) met the inclusion criteria in both recent systematic reviews that the National Academies of Sciences, Engineering, and Medicine judged to be the most comprehensive and rigorous (15, 16) . Two of these (13, 14) focused exclusively on patient populations and as such are not generalizable to the general population. All the others were considered to have significant methodological flaws that limited the quality of conclusions, including lack of identification and control of known prognostic factors for successful cessation. In particular, higher nicotine dependence is positively associated with use of a cessation aid as well as negatively associated with cessation success. Another National Academies of Sciences, Engineering, and Medicine criticism focused on the inclusion of participants who were using e-cigarettes for reasons other than as a cessation aid. Additionally, there was an expressed concern that relapsed smokers might not have recalled all of their unsuccessful quit attempts or had degraded their significance by recalling them as "not really a quit attempt." This proposed pattern of differential recall of past quit attempts could lead to a bias toward fewer recalled failures (17, 18) . However, the suggestion that this recall bias is differential according to use of cessation aids is not convincing (19) .
Understanding the potential role that ENDS products may play in cessation requires direct comparisons with recommended efficacious pharmaceutical products (varenicline, bupropion, and nicotine replacement therapy (NRT)) (20) . The effectiveness of the dissemination of these aids at the population level has been questioned (21) , and these findings need replication.
In this study, we used the first 2 waves from the large, nationally representative PATH Study (22) to evaluate the influence of ENDS and pharmaceutical cessation aids on persistent abstinence (≥30 days) from cigarettes as well as reduced cigarette consumption, using propensity score matching (PSM) to balance comparison groups on potential confounders.
METHODS

Data source
The federally funded PATH Study (23) drew an address-based area probability sample of the noninstitutionalized US population for Wave 1 and completed in-household audio-computer-assisted self-interviews in English and Spanish in 2013-2014. Westat's Institutional Review Board approved the PATH Study design/ protocol, and the Office of Management and Budget approved the data collection. Oversampling was undertaken for tobacco users, African Americans, and young adults aged 18-24 years. In this adult sample, the Wave 1 weighted response rate was 74%, and there were 10,851 who reported current smoking (i.e., regularly smoking cigarettes every day or some days). Approximately 1 year after the Wave 1 interviews, a similar in-household self-interview (Wave 2) was undertaken, and 8,861 (81.7%) of the Wave 1 "current smokers" were reinterviewed. Of these, 5,712 (64.5%) did not report a quit attempt prior to Wave 2, and 56 had incomplete details on their quit attempt, leaving a sample of 3,093 for this analysis.
Measures
Tobacco use status. During the interview at both waves, participants were shown pictures of tobacco products prior to responding to questions about use. At Wave 1, all current cigarette smokers (every-day or some-days users) were queried on the frequency of use in the previous 30 days, number of cigarettes consumed per day, and how old they were when they first started smoking fairly regularly. For other tobacco products, a regular current user was identified with the questions: "Do you now use [PRODUCT] every day, some days or not at all?" and, "Have you ever used [PRODUCT] fairly regularly?"
At Wave 2, all current regular users from Wave 1 were asked "In the past 12 months, have you tried to quit [PRODUCT]?" Those who responded "not at all" to the current use question at Wave 2 were asked, "About how long has it been since you last [smoked/used PRODUCT]?" Because use in the previous month indicates current use for some products, we used ≥30 days of abstinence at Wave 2 (persistent abstinence) as an early marker of successful cessation for both cigarettes and all forms of tobacco other than ENDS.
At Wave 2, those who reported a quit attempt in the previous year were asked about use of each of the following products during that attempt (allowing multiple product use): ENDS (e-cigarettes), NRT (nicotine patch, gum, inhaler, nasal spray, lozenge, or pill), varenicline (Chantix; Pfizer, Groton, Connecticut), and bupropion (Wellbutrin or Zyban; GlaxoSmithKline, Brentford, London).
Smoking history. Age of cigarette smoking initiation was assessed with the question, "How old were you when you first started smoking fairly regularly?" (coded as <18 years old or ≥18 years old). Quitting history prior to Wave 1 was also queried.
All respondents were asked, "Which statement best describes the rules about smoking inside your home?" The response, "It is not allowed anywhere or at any time inside my home" indicated a smoke-free home. Time spent around other smokers was assessed using the question, "During the past seven days, about how many hours were you around others who were smoking (whether or not you were smoking yourself)? Include time in your home, in a car, at work, or outdoors." Beliefs about the harmfulness of e-cigarettes were assessed using the question "Is using e-cigarettes less harmful, about the same, or more harmful than smoking cigarettes?" (coded as "less harmful" or all other responses). A psychometrically valid scale of dependence on tobacco products was developed from multiple questions on the PATH survey (24) .
Sociodemographic characteristics. The PATH Study contains detailed information on a number of standard sociodemographic characteristics. Respondent's age was queried in individual years, which we reduced to 2 categories for this study: 18-34 years and ≥35 years.
We used binary classifications for sex, educational status (college graduate vs. less than college graduate), and race/ethnicity (non-Hispanic white vs. other). Our binary classification of educational attainment highlighted college graduates, who have a much higher successful cessation rate than other education groups.
Multiple imputation. Missing data were observed on a few of the variables we assessed (Web Table 1 , available at https:// academic.oup.com/aje). Missing data were imputed using the Amelia II algorithm in R (R Foundation for Statistical Computing, Vienna, Austria) with 5 imputed data sets, and by assuming a missing-at-random pattern (25) . Natural logarithm transformation improved normality of 3 continuous variables and was used for imputation (Web Figure 1) . Imputation diagnostics suggested that the Amelia II algorithm provided imputed values well within range of observed values (Web Figure 2 ) and accurately predicted the majority of the observed values for the continuous variables (Web Figure 3) .
Statistical analysis
Frequencies of cessation-aid use and cigarette and tobacco abstinence were described across sociodemographic and smoking characteristics, using complete cases for each comparison, and the statistical significance for bivariate differences was tested using weighted χ 2 tests. PSM was used to choose a comparison group of respondents for each "treatment" group (e.g., ENDS, varenicline, bupropion, and NRT) that balanced the groups with respect to potential confounders. Matching algorithms were optimized separately for each cessation aid group to assess quitting rates and then again for relapsers at Wave 2 to assess levels of consumption. For each cessation aid product group, we compared users with nonusers and also compared the group of ENDS users with the group who used any approved pharmaceutical aids.
To calculate propensity scores, we first obtained imputed data sets, then optimized logistic models and estimated propensity scores, and finally averaged the propensity score for each individual across the data sets (26) . Separate logistic models were fitted for each of the imputed data sets, with each cessation aid group as an outcome and potential confounders entered as covariates in the regression equation. Likelihood ratio tests (27) were used to assess whether continuous model coefficients should be specified as either a quadratic or a linear function depending on the cessation aid of interest (Web Tables 1 and 2) . After identifying the best-fitting specifications, we estimated each respondent's propensity to use a product from each of the cessation-aid groups, and we averaged the final resulting propensity score for each individual across imputations (26) .
Using the resulting propensity scores, each cessation-aid user was matched to the closest nonuser(s) using the nearestneighbor method with optimizations assessed for choice of matching ratios and caliper (28) . Standardized mean differences of each covariate were used to judge whether the matching improved balance across all imputed data sets (Web Tables 3-12) . We chose the ratio and caliper that provided the lowest average imbalance across all imputed data sets and assured covariates had standardized mean differences that were <|0.1|. Our final ratio and caliper decisions are provided in Web Table 13 .
We then estimated differences in cigarette and tobacco abstinence at Wave 2 with pairwise comparisons among each cessation-aid user group and subsequently for ENDS users versus users of any approved pharmaceutical cessation aids. Further, among relapsers, we estimated the association of cessation aid use with cigarette consumption at Wave 2. For the models predicting cigarette and tobacco abstinence, risk differences and their corresponding 95% confidence intervals were calculated using logistic regression and by using 1,000 draws from the multivariate normal distribution with the mean vector equal to the model coefficients and the variance equal to the coefficient covariance matrix (29) . For the models predicting cigarette consumption, mean differences and 95% confidence intervals were calculated using ordinary least squares (OLS) regression. We also checked whether assuming a negative binomial distribution altered effect size. All covariate coefficient values were centered at their means. All analyses were performed using R, version 3.4.3 (R Foundation for Statistical Computing), all tests for descriptive analyses were 2-tailed, and significance tests were adjusted for multiple comparisons (α = 0.05/12).
RESULTS
Characteristics of the sample
Just over half the population of quit attempters (53%) were men, 43% were under the age of 35 years, 68% were non-Hispanic white, and 88.5% did not have a college degree. Of these demographic factors, only having a college degree was associated with persistent cigarette abstinence at Wave 2 (20.0% (standard error (SE), 2.3) vs. 14.9% (SE, 0.8)) ( Table 1) . Persistent tobacco abstinence (≥30 days) was achieved at Wave 2 by 9.6% (SE, 0.6) of these quit attempters, however 15.5% (SE, 0.8) were persistently abstinent from cigarettes. Of these quit attempters, three-fourths (76%) were daily smokers, with half smoking 10-20 cigarettes per day; 41% reported no quit attempt in the year prior to baseline.
In terms of use of cessation aids, 25.2% used ENDS, while 23.5% used at least 1 approved pharmaceutical cessation aid (NRT, 18.7%; varenicline, 5.7%; bupropion, 3.1%) ( Table 1) . Of those who used a cessation aid, 15.1% reported using more than 1 product, with the largest proportion of these using ENDS and NRT together (13.5%). Compared with those under age 34 years, a greater proportion of older quit attempters were users of approved pharmaceutical products, while fewer used ENDS as a cessation aid (22.8% (SE, 1.1) vs. 28.3% (SE, 1.4)). Overall, 84.5% of this population had relapsed to cigarette smoking by time of the Wave 2 survey (Table 1) .
Measures of nicotine dependence at Wave 1 were associated with greater likelihood of using a cessation aid in the quit attempt and a lower chance of being cigarette abstinent at Wave 2. For cigarette consumption, this effect was seen only among those who smoked ≥10 cigarettes/day compared with those who smoked less. The more time spent with other smokers, 16 .8% (SE, 1.1) for those exposed 1-10 hours). There was no difference in use of cessation aids among smokers who had a smoke-free home at Wave 1, although those with a smoke-free home were also more likely to be cigarette abstinent at Wave 2 (18.1% (SE, 1.0) vs. 12.1% (SE, 0.9)). Among quit attempters, one-fourth of those who used ENDS for the target quit attempt also used ENDS at Wave 1 (6.6/18.7 + 6.6) ( Table 2 ). Wave 1 use of ENDS made no difference in the proportion who had substituted e-cigarettes for cigarette smoking at Wave 2 follow-up. Persistent abstinence from all tobacco at Wave 2 was lower in those using ENDS to quit than other groups. Of the additional 6% who were persistently cigarette abstinent, but not persistently tobacco abstinent at Wave 2, 73% (4.4/6.0) were ENDS users at Wave 2, including some who reported using other cessation methods in their quit attempt. At Wave 2, there was significant dual use of cigarettes and ENDS among relapsed smokers from all cessation-aid user groups, with the highest dual use from those who had used ENDS at Wave 1 (60.7% (SE, 4.6)).
Achieving comparable groups with matching
Comparison of the standardized mean differences identified imbalance across the cessation-aid user groups on many of the covariates we assessed in the unmatched data set (Web Tables 3-12 ). However, after matching, the standardized mean differences of each covariate included were systematically below 0.1.
Matching improved the comparability of groups. Matched samples were well-balanced with respect to the covariates that we assessed (Web Tables 3-12) .
Helpfulness of cessation aids
In Figure 1A , we present the association between the use of each of the cessation aids and abstinence from cigarettes. Using ENDS to try to quit cigarette smoking increased the probability of abstinence from cigarettes (risk difference (RD) = 5%, 95% confidence interval (CI): 1, 10; or odds ratio = 1.52, 95% CI 1.14, 2.02). Both varenicline (RD = 3%, 95% CI: −5, 12) and bupropion (RD = 8%, 95% CI: −2, 21) had positive risk differences that were not significant, whereas NRT (RD = −3%, 95% CI: −8, 3) had a negative but nonsignificant risk difference for persistent abstinence from cigarettes. However, when comparing ENDS users with those using any pharmaceutical aid (using ENDS but not varenicline, bupropion, or NRT), we did not detect a difference in abstinence from cigarettes (RD = 3%, 95% CI: −3, 10).
We also present the association between the use of each of the cessation aids for reduction of cigarette consumption among those who had relapsed to cigarette smoking at Wave 2 ( Figure 1B) . ENDS use was not associated with lower average daily cigarette consumption at Wave 2 (cigarettes per day, −0.34, 95% CI: −1.42, 0.75). Similarly, the use of varenicline, bupropion, or NRT to aid the quit attempt was not associated with lower average daily cigarette consumption at Wave 2, and ENDS users were not different from pharmaceutical aid users. Assuming a negative binomial distribution did not alter effect size or statistical significance (Web Figure 4) .
DISCUSSION
In this nationally representative study, approximately onethird of baseline smokers reported a ≥1-day quit attempt during the year prior to the second interview. Of these quit attempters, almost half (48.7%) used a cessation aid to help them quit. The most common cessation aids used were ENDS (25.2% of all quit attempters), suggesting that smokers may lack confidence in pharmaceutical cessation aids. Using a subsample balanced through PSM, we estimated that using ENDS increased the probability of persistent abstinence from cigarettes by 6%. Both varenicline and bupropion had a positive risk difference for quitting; however, neither was statistically significant. There was also no statistically significant difference when comparing users of ENDS as a cessation aid with users of approved cessation aids.
The vast majority (79%) of quit attempters had relapsed back to cigarette smoking by the time of the Wave 2 survey. Of those who used ENDS to quit, over 70% were still using ENDS at Wave 2, and the majority of them were smoking cigarettes as well. Among relapsers at Wave 2, there was no evidence that using ENDS to quit was associated with lower cigarette consumption. Thus, there is a distinct possibility that a subgroup of dual users at Wave 2 may have higher levels of nicotine intake, which may make it harder for them to quit smoking cigarettes in the future (30) , emphasizing the need for continued monitoring of this population.
Berry et al. (31) also recently analyzed data from the PATH Study to evaluate the association of recent e-cigarette use with cigarette abstinence; their analysis was different from ours in that it did not consider the reason for using e-cigarettes. Because 75% of smokers believe e-cigarettes help cessation (5), the inclusion of non-quit-attempters in the analysis will bias the main findings in favor of e-cigarettes aiding cessation. Another important difference is that they conducted a traditional multivariable analysis. Given the important improvement in comparability of exposed and unexposed groups through the use of PSM, it is unlikely that the study adequately controlled for the many baseline potential confounders. An interesting finding was that the association between 30-day cigarette abstinence and e-cigarettes was limited to daily use of e-cigarettes at Wave 2, achieved by only a minority of users. A limitation of both of these studies is that abstinence was limited to a relatively short time period (30 days) prior to Wave 2. With relapse to smoking still considerable through 12 months after quitting (32), these findings must be confirmed at least through another year (e.g., Wave 3 of the PATH Study). A) Difference in the probability of remaining abstinent from cigarette smoking for at least 30 days; B) difference in cigarette consumption among smokers who had relapsed to using cigarettes. Cigarette consumption was assessed only among smokers who had relapsed to using cigarettes. "Pharma alone" indicates using any of the approved pharmaceuticals but not electronic nicotine delivery systems (ENDS). CI, confidence interval; NRT, nicotine replacement therapy; RD, risk difference.
A strength of our study is that we were able to compare the relative effectiveness of ENDS used as a cessation aid with the effectiveness of other recommended cessation aids. While we did not detect an association of use of pharmaceutical cessation aids with cigarette abstinence, we also did not detect a difference in using ENDS as a cessation aid compared with use of a pharmaceutical aid. Part of this issue relates to the paucity of US smokers who used an approved cessation aid as well as with the size of the observed association.
The PATH Study is a large, address-based sample that is representative of the US population. Our choice of persistent abstinence as our outcome measure is supported as an earlier indicator of success given that only 15% of quit attempters in this study achieved this level of abstinence. Because the PATH Study has additional annual data collections, it will be possible in the future to better describe both long-term relapse among those who were persistently abstinent at Wave 2 and developing patterns of ENDS and cigarette use. Our study indicates that some key potential predictors of abstinence (such as tobacco-dependence measures) are also associated strongly with choice of a cessation aid, including an ENDS product. We used PSM, which offers a way to achieve baseline comparability of study groups (thus mimicking one of the goals of randomized trials) (33) prior to undertaking an analysis on the outcome of interest.
In conclusion, our results indicate that ENDS are a more popular choice than approved pharmaceutical products as a smoking cessation aid among US quit attempters, over threefourths of whom were daily smokers. In the future, as ENDS products continue to evolve to make nicotine delivery more similar to that obtained from a cigarette (34) , it is possible that they may play a bigger role in assisting smokers to quit combustible tobacco (35) . In parallel, using ENDS as a cessation aid resulted in dual use among relapsers; it did not reduce their cigarette consumption but rather appeared to expose them to potential additional risk.
